Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban/Apixaban versus Heparin/Enoxaparin after gynecologic oncologic surgery
IRCT20220211053991N1Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jun 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rivaroxaban, apixaban, heparin and enoxaparin in gynecological cancer (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Bleeding in organs, Limb size disorder and 6 more. Started Jun 2023; status: completed.
02
Drugs
rivaroxabanapixabanheparinenoxaparin
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on IRCT20220211053991N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220211053991N1.